Immunological evaluation of personalized peptide vaccination for patients with pancreatic cancer.
Immunological evaluation of personalized peptide vaccination for patients with pancreatic cancer.
复制标题
DOI：
10.3892/or.13.5.874
复制
发表时间：
2005-05
期刊：
影响因子：
4.2
通讯作者：
Koutaro Yamamoto;T. Mine;K. Katagiri;N. Suzuki;Toru Kawaoka;T. Ueno;S. Matsueda;A. Yamada;K. Itoh;H. Yamana;M. Oka
中科院分区：
文献类型：
--
作者：
Koutaro Yamamoto;T. Mine;K. Katagiri;N. Suzuki;Toru Kawaoka;T. Ueno;S. Matsueda;A. Yamada;K. Itoh;H. Yamana;M. Oka
胰腺癌的预后极差，需要开发新的治疗方式。一种这样的治疗可以是特异性免疫疗法。为了评估安全性和免疫应答，我们对胰腺癌患者（n=11）进行了个性化肽疫苗接种的I期研究。即，在HLA-A24（+）或-A2（+）患者中，筛选接种前外周血单核细胞对14种或16种肽中的每一种的体外反应性，并且仅在体内接种反应性肽（最大值：4）。尽管在7例患者中观察到注射部位的炎症反应，但该方案通常耐受良好。在7名患者中观察到对用于疫苗接种的肽的迟发型超敏反应。在分别来自4/8名受试患者和4/10名受试患者的疫苗接种后PBMC和血清中观察到对用于疫苗接种的至少一种肽的细胞和体液免疫应答增加。接受>3次疫苗接种的患者（n=10）的6个月和12个月生存率分别为80%和20%。由于耐受性和诱导特异性免疫的能力，进一步开发用于胰腺癌患者的个性化基于肽的免疫疗法是必要的。
The prognosis of pancreatic cancer is extremely poor, and development of new treatment modalities is needed. One such treatment could be specific immunotherapy. To evaluate safety and immunological responses, we conducted a phase I study of personalized peptide vaccination for pancreatic cancer patients (n=11). Namely, pre-vaccination peripheral blood mononuclear cells were screened for their reactivity in vitro to each of 14 or 16 peptides in HLA-A24(+) or -A2(+) patients, and only the reactive peptides (maximum: 4) were vaccinated in vivo. This regimen was generally well tolerated, although inflammatory reactions at the injection site were observed in 7 patients. Delayed-type hypersensitivity to peptides used for vaccination was observed in 7 patients. Increased cellular and humoral immune responses to at least one of peptides used for vaccination were observed in the post-vaccination PBMCs and sera from 4 of 8 patients and 4 of 10 patients tested, respectively. The 6- and 12-month survival rates for patients who received >3 vaccinations (n=10) were 80% and 20%, respectively. Due to tolerability and capability of inducing specific immunity, further development of personalized peptide-based immunotherapy for pancreatic cancer patients is warranted.